- Conditions
- Glioblastoma, Glioma
- Interventions
- GDC-0084
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 2,386
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Apraxia Speech
- Interventions
- Transcranial Magnetic Stimulation (TMS)
- Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more
- Conditions
- Germline Mutation in the NOTCH 3 Gene, Cardiovascular Disease, Arterial Stiffness, Pathogenesis of CADASIL, Clinical Phenotype of CADASIL
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Columbus, Ohio
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Olaratumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Bakersfield, California • Highland, California + 17 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Torrington, Connecticut • Ocala, Florida + 39 more
- Conditions
- Brain and Central Nervous System Tumors, Sarcoma
- Interventions
- vatalanib
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Seattle, Washington
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Davunetide, Placebo
- Drug
- Lead sponsor
- Allon Therapeutics
- Industry
- Eligibility
- 41 Years to 85 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
- Conditions
- Head and Neck Cancer, Cancer Survivorship, Treatment-related Muscle Loss, Physical Function
- Interventions
- Creatine Supplementation, Resistance Training
- Dietary Supplement · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Rhabdomyosarcoma, Refractory Rhabdomyosarcoma
- Interventions
- PEEL-224, Vincristine, Temozolomide (TMZ)
- Drug
- Lead sponsor
- Theodore Laetsch
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Lung Diseases, Respiratory Distress Syndrome, Newborn, Pulmonary Surfactant, Lung Diseases, Interstitial
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 5,176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Head and Neck Neoplasms
- Interventions
- paclitaxel albumin-stabilized nanoparticle formulation, Cisplatin, Fluorouracil, Intensity modulated radiation therapy, Cetuximab, Quality-of-life assessment
- Drug · Radiation · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Major Depressive Disorder, Mood Disorders
- Interventions
- Rumination-Focused CBT, Relaxation-based Therapy
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 14 Years to 17 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Salt Lake City, Utah
- Conditions
- Peripheral Artery Disease
- Interventions
- Assistive tennis shoes
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Renal Cell Carcinoma, Metastatic
- Interventions
- Intuvax (INN: ilixadencel), Sunitinib
- Biological · Drug
- Lead sponsor
- Mendus
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Saint Paul, Minnesota + 1 more
- Conditions
- Overweight and Obesity
- Interventions
- Exercise Protocol, Calorie-Restrictive Low Carbohydrate Diet (CR-LC), Ancestral Diet (AD)
- Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Cancer, Physical Function
- Interventions
- Progressive Resistance Training Exercise, Flexibility and Balance Exercise
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 60 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Ofatumumab, Disease modifying treatment (DMT)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more
- Conditions
- Multiple Sclerosis
- Interventions
- BG00012 (DMF) (Tecfidera®.)
- Drug
- Lead sponsor
- Multiple Sclerosis Center of Northeastern New York
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Latham, New York
- Conditions
- Glioma
- Interventions
- bevacizumab, carmustine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Interventions
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Biological · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
- Interventions
- Lenalidomide, Dexamethasone, Rituximab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV Infections, Leukoencephalopathy, Progressive Multifocal
- Interventions
- Filgrastim, Cytarabine, Zidovudine, Zalcitabine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1997
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma, Glioma
- Interventions
- Selumetinib
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 45 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio